Canada: Cannabis In Canada: A Changing Legal Landscape

The anticipated legalization of recreational cannabis in Canada by July 2018 is multi-faceted. Several areas of law will come into play, potentially impacting many types of businesses. We delve into some of these areas below.


Canadian Capital Markets

As changes in the regulatory regime open up significant opportunities in the cannabis sector, industry players will be seeking access to capital to fund growth, and investors will be looking for a means by which to participate in this emerging market. While cannabis industry participants in the United States face challenges to obtaining public listings on the U.S. stock exchanges due to the lack of harmonization between the U.S. federal and state regimes, Canada has already seen 37 successful cannabis industry listings, with potential for more on the horizon. Canada has three stock exchanges: the Toronto Stock Exchange, the largest exchange; the TSX Venture Exchange, an exchange generally composed of more junior issuers; and the Canadian Securities Exchange, which was formed as a competitor to the TSXV, which markets to entrepreneurs. The TSX currently has approximately 1,500 listed companies, with a quoted market value of more than C$2.2-trillion. The TSXV's approximately 1,800 issuers have a quoted market value of more than C$23-billion. Currently there are 300 listed companies on the CSE, with a quoted market value of approximately C$4.3-billion. Of the 37 cannabis industry participants listed in Canada, 26 have listed on the CSE, eight on the TSXV and three issuers on the TSX. Eight of these industry participants are licensed producers under the Access to Cannabis for Medical Purposes Regulations and 22 are headquartered in British Columbia.

Obtaining a Listing in Canada

One consideration for cannabis issuers and investors looking to cash in on their rising sector is proper positioning to take a company public, which includes operating in a manner that complies with rules and policies of the applicable exchange. Issuers can obtain a listing through a traditional initial public offering, or a more common avenue for emerging companies in the cannabis industry — a reverse take-over of an existing listed issuer. A reverse take-over often involves an amalgamation or issuance of securities of a listed shell company in exchange for assets or securities of the private company, resulting in the private company effectively "going public." Whereas a traditional public offering can raise timing issues and uncertainty depending on market movements, a reverse take-over may provide a more practical means of providing its initial investors with desired liquidity. At the right valuation, the reverse take-over can be an efficient alternative where a conventional prospectus financing is unfeasible or impractical, and for newly emerging companies provides the benefits of a public listing, secondary market liquidity and access to the capital markets.

Access to Capital in Canada and U.S.

Cannabis industry participants on each of the Canadian exchanges have already found success accessing capital through the Canadian markets conducting public offerings and private placements under the Canadian regime. As these issuers become more financially robust, we expect to see more graduations up to the larger exchanges with Canada poised to becoming the capital market of choice for issuers and investors. Once a company obtains a TSX listing, it could take advantage of the multi-jurisdictional disclosure system (MJDS) to access capital in the United States. The MJDS regime is a system adopted by the U.S. Securities and Exchange Commission (SEC) and the Canadian Securities Administrators to facilitate cross-border public offerings of securities. MJDS allows Canadian-listed issuers on the TSX that meet certain eligibility requirements to satisfy disclosure rules in the United States through compliance with the Canadian regime. The reverse is true for U.S. issuers raising money in Canada. The regime is particularly beneficial to companies listed in Canada who are looking to access U.S. capital as they are permitted to use Canadian style disclosure, comply with Canadian corporate governance practices and work with their local regulator on all requisite approvals as opposed to the SEC.


The pending legalization of non-medical cannabis raises a host of issues for employers. Upon passage of the new legislation, employers can expect to encounter difficult decisions relating to the appropriateness of drug testing (including suitability of any current drug-testing programs), dealing with drug-related employee misconduct and claims of discrimination, and the ever delicate balance between the obligation to accommodate an employee with a disability (including an addiction) under human rights legislation and the duty under occupational health and safety legislation to provide employees with a safe workplace.

In addition to reviewing and amending workplace policies and procedures in light of the new legislation, we recommend that our clients seek legal advice when dealing with those workplace issues that will inevitably arise with the legalization of recreational cannabis.


Bank Act

The Bank Act gives scheduled banks the right to take security interests in farm assets, crops and other agricultural products in exchange for the extension of credit. When a borrower makes a grant of security under the Bank Act, title to the pledged asset is deemed to transfer to the lender. As a result, unique issues arise where Bank Act security is taken in respect of an agriculture product that is also a controlled substance, such as cannabis. Accepting a security interest in cannabis may result in the lender holding title to a controlled substance and may increase the risk of exposure to possible regulatory or criminal liability. That being said, the decision as to whether or not to take Bank Act security will involve a balancing of the limitations of existing Personal Property Security Act (PPSA) security as against the legal and reputational risk of taking a grant of Bank Act security. Where cannabis may constitute all or part of the collateral securing a loan, it is important for lenders to consult counsel in order to design an appropriate security package to limit exposure and maximize coverage.


There is considerable uncertainty across Canada as to whether a licensed producer can grant, and a creditor can take, a security interest in a producer's licence, as courts have not yet had the opportunity to determine whether a producer's licence is an "intangible" for the purposes of the respective provincial PPSAs. However, the uncertainty over whether a producer's licence constitutes "intangible" property for the purposes of the respective PPSA should not affect the nature of the security documentation. In a properly drafted security document, a typical grant of a security interest from a borrower will attach to all of its present and after-acquired assets, property and undertakings. It is also typically subject to the usual carve-out for restricted assets. As a result, where a producer's licence is capable of being charged, it will be. If not, then a lender should consult counsel to ensure that the security package provides for secondary or overlapping coverage.


The new legislation will inevitably result in a flurry of discussions between the government and affected stakeholders. For our clients who are planning to engage government officials (elected or otherwise) regarding the new regime, it will be important to consider applicable laws related to communicating with public office holders, particularly with respect to lobbying registration requirements and access-to-information matters.


Cannabis, similar to any other commodity, is subject to Canada's customs laws respecting international trade in goods. However, in the case of cannabis, additional rules apply regarding the fact that trade in cannabis is subject to international agreements or arrangements to which Canada is a party.

In the case of importations of goods, Canada's Customs Tariff, Customs Act, and Export and Import Permits Act are the primary regulatory statutes. An importer is required to satisfy certain notification, reporting, release and accounting obligations in order to import goods into Canada. The importer must also have a business number and import account. This is in addition to any licences and/or import permits that the importer may be required to apply for/obtain from the Canada Border Services Agency (CBSA), Global Affairs Canada (GAC), Health Canada, Canadian Food Inspection Agency (CFIA) or other regulatory agencies or bodies.

In the case of exportations of goods, Canada's Customs Act and Export and Import Permits Act are the primary regulatory statutes. An exporter is required to satisfy certain export reporting requirements under the Customs Act and must ensure that any export permits necessary for the exportation of the goods are obtained from GAC or other relevant regulatory agency or body. In the case of exports, the exporter should also confirm that the goods are not being shipped or that there are no dealings with sanctioned countries, individuals or entities under Canada's Special Economic Measures Act, United Nations Act or any other sanctions-related acts and associated regulations. The exporter must also have a business number and exporter account. This is in addition to any licences and/or export permits that the exporter may be required to apply for/obtain from the CBSA, GAC, Health Canada, CFIA or other regulatory agencies or bodies. The exporter must also ensure that the cannabis being exported may lawfully be imported into the destination jurisdiction and that any approvals, licences, permits or other requirements are satisfied.


The extent to which the new law will restrict the advertising and branding of cannabis was, and still is, one of the key unknowns. From industry's perspective, cannabis should be regulated more like alcohol than tobacco, and the ability to brand their products (rather than sell only in plain packaging) is essential to properly compete with the black market and makes it more difficult to have counterfeit product. In contrast, many public health, law enforcement and youth experts believe strict controls are needed to minimize the risks of cannabis promotion to youth, given the challenges with partial restrictions (i.e., only prohibiting advertising that targets youth).

The Task Force on Marijuana Legalization and Regulation recommended that advertising and promotion of cannabis be strictly regulated and products only sold in plain packaging (similar to the global trend with tobacco). However, the current version of the Cannabis Act's (Act) restrictions on promotion and packaging presently fall in-between those advocated by industry and those advocated by public health and other experts.

The Act prohibits any promotion of cannabis, a cannabis accessory or a service related to cannabis, as well as any packaging, that (1) uses testimonials or endorsements; (2) depicts a person, character or animal (real or fictional); (3) constitutes lifestyle advertising (e.g., associated with a way of life involving glamour, recreation, excitement, vitality, risk or daring); or (4) is directed to young persons. Whether plain packaging will be required once regulations are introduced remains to be seen. Sponsorships are also prohibited under the Act, and promotion on the basis of price or distribution is restricted. Further, to pre-empt the use of foreign media as a loophole, the Act also explicitly prohibits the use of foreign media to promote cannabis, an accessory or service if the promotion would otherwise have been prohibited under the Act. Informational promotion or brand-preference promotion is permitted in limited circumstances (e.g., in a place where young persons are not permitted by law).

In addition to cannabis-specific restrictions, industry must remember to comply with all of the general advertising, anti-spam and privacy laws that apply to all businesses. This is especially important since a flood of class actions are expected once the private right of action comes into force on July 1, 2017, for contraventions of Canada's Anti-Spam Legislation as well as certain types of misleading advertising under the Competition Act.

There are unique privacy considerations with cannabis. For example, as privacy laws for personal information versus personal health information differ, businesses will need to keep this in mind once cannabis is legal for both medical and recreational purposes. Also, for both privacy and safety/diversion reasons, there may be issues with having packaging, or even an envelope, that identifies the recipient as someone who may have cannabis. A privacy class action against the Government of Canada is pending because several years ago Health Canada sent mail to certain Canadians that inadvertently referenced "Marihuana Medical Access Program" in combination with the addressee's name on the envelope.

Even once recreational cannabis is lawful, edibles are not likely to be permitted until a later date. Once permitted, those in the edibles business will need to ensure compliance not only with cannabis-specific laws (e.g., cannot be appealing to young persons, cannot contain any substance designated as prohibited such as caffeine, potentially), but any applicable general food laws too. The task force report specifically recommended that the labelling requirements that apply to food and beverages generally also apply to edibles. At a federal level, the food industry is undergoing some of the most significant developments and consultations in decades (including the Safe Food for Canadians Act), and any business interested in edibles should ensure it is familiar with all applicable regulatory regimes (from federal to municipal). For example, notwithstanding that dispensaries are currently illegal throughout Canada (due to federal law), some municipalities have chosen to regulate these businesses and it is interesting to note the difference in treatment of edibles, even within the same province (e.g., the City of Vancouver has banned dispensaries from selling edibles, while the City of Victoria has not, despite both being in the province of British Columbia).


The licencing, sale and use of cannabis (both medically and recreationally) is likely to result in an increased risk of product liability claims on behalf of patients and consumers, including class action risk for the industry, both at the level of the producer and throughout the chain of distribution. Historically, product liability — particularly claims involving pharmaceutical medicines — has been a focus for the plaintiffs' class action bar in Canada, and some specific focus on cannabis has already occurred and is expected to continue. In that regard, proposed class actions were recently commenced in both Ontario and Nova Scotia against a federally regulated producer in which allegations of "negligent design, development, testing, manufacturing, and distribution" have been made after alleged unapproved pesticides were found in the product and ingested. Like other products that have risks and benefits inherent to their use, producers and distributors of cannabis should carefully consider their quality and manufacturing control processes, product warnings and proactive strategies for dealing with consumer complaints, recalls and litigation risk generally.


Sales of illegal marijuana have long been subject to tax in Canada (notwithstanding the illegality of the sales), and legal sales of medical marijuana are also currently treated as taxable. From the outset, the federal government stated its intention to "legalize, tax and regulate marijuana" in a discussion paper by the Task Force on Marijuana Legalization and Regulation. While the function of tax is primarily to raise revenues for government, in the case of cannabis it has been suggested that tax may also serve certain policy-oriented ends, including:

  • Managing price and discouraging consumption, particularly among youth
  • Funding programs associated with cannabis legalization and paying for negative external costs of cannabis use to society (e.g., enforcement and dependence treatment), as discussed in a recent report by the Office of the Parliamentary Budget Officer.

The task force advised the federal government to work with provincial and territorial governments when crafting a tax regime for legal cannabis to ensure that prices are competitive with the illicit drug market. However, another explicit recommendation was that the tax scheme should be based (at least in part) on THC potency to discourage purchases of high-potency products with higher prices, as discussed in the task force's final report.

The government has several existing models of taxes to choose from to implement these tax recommendations, including (1) sales taxes at the point of sale, based on purchase price (e.g., GST/HST or PST), (2) excise taxes payable by producers, per unit or by weight/volume (similar to alcohol and tobacco), and (3) additional taxes, whether charged at point of sale or by producers, based on potency or other considerations. The federal budget published on March 22, 2017, implied that any excise tax rates imposed on cannabis will rise over time, perhaps adjusted to the Consumer Price Index, similar to the new regime that was announced for alcohol. If the government does decide to impose excise or other taxes on producers, it will also have to consider how the tax authorities will enforce the rules to ensure that producers do not under-report their production for tax purposes.

One additional point that should be addressed by the government is the distinction between medical and recreational cannabis sales. Normally, prescription drugs are zero-rated (i.e., not subject to GST/HST). Based on existing jurisprudence, which interprets the term "prescription" narrowly, medical marijuana is considered to be subject to GST/HST because it is not prescribed, but rather a physician provides a declaration of support for an individual's application for an Authorization to Possess under the Marihuana Medical Access Regulations (SOR/2001-227). Both the Tax Court of Canada and the Federal Court of Appeal have noted that the legislation "needs work."

The task force recommended that the same tax system for medical and non-medical cannabis products should be applied, while recognizing that cannabis and cannabinoid-based medicines could be developed that are prescribed as medications and zero-rated for GST/HST purposes. Meanwhile, the Canada Revenue Agency has confirmed that it will allow the costs of medical marijuana purchased from a licensed producer as a medical expense for income tax purposes.

The forthcoming legislation presents an opportunity for the government to clarify the tax treatment of medical marijuana and make any appropriate price/tax distinctions between medical and recreational products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
30 Oct 2019, Other, Toronto, Canada

The materials on the Blakes Business Class website are provided for informational purposes only. Accessing this information does not create a lawyer-client relationship.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions